Navigation Links
Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
Date:5/10/2013

INDIANAPOLIS, May 10, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL). The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were consistent with previously disclosed studies.

"We are disappointed in the results that we're announcing today," said Richard Gaynor , M.D., vice president, product development and medical affairs for Lilly Oncology.  "However, our oncology pipeline is still one of the most robust across the industry containing more than 20 molecules, including two Phase III molecules in five different tumor types."

Lilly plans to present data from this study at an upcoming scientific meeting.

Lilly will stop development of enzastaurin, which is expected to result in a second-quarter charge to R&D expense of approximately $30 million. The company's previously-issued financial guidance for 2013 remains unchanged.

About the Study
Patients enrolled in PRELUDE had histologically confirmed DLBCL with an International Prognostic Index (IPI) score of three to five at diagnosis. The IPI is a simple, clinical tool that is used to predict survival outcomes for patients with DLBCL. Patients enrolled also achieved a complete response or complete response-unconfirmed to cyclophosphamide, doxorubicin, vincristine, and prednisone, plus rituximab (R-CHOP) therapy. Patients were randomized in a 2:1 fashion to receive enzastaurin or placebo.

Treatment continued until patients developed progres
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery
2. Lilly Declares Second-Quarter 2013 Dividend
3. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
4. The Importance of Emergency Preparedness: Lilly Diabetes and the American College of Endocrinology (ACE) Help Prep People with Diabetes for Emergencies - Big or Small
5. Lilly Diabetes and Disney Publishing Worldwide Expand Collaboration
6. Lilly Celebrates National Volunteer Week with Deployment of Global Service Teams
7. Lilly Again Named One of DiversityIncs Top 50 Companies for Diversity
8. Lilly Reports First-Quarter 2013 Results
9. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
10. Lilly Confirms Date and Conference Call for First-Quarter 2013 Financial Results Announcement
11. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  UBM Medica US announces that ... oncologists, presents exclusive slide shows dealing with communication in ... cancer care. Cancer Network, the ... news, blogs, and podcasts about the latest clinical findings. ... , End-of-life care is challenging for even ...
(Date:7/31/2014)... BURLINGTON, Mass. , July 31, 2014 ... healthcare funding changes brought about by the ... both reimbursement and prescribing of pharmaceutical therapies. ... (MCOs) cover beneficiaries through new regulations and ... is occurring in the health exchanges—state-based marketplaces ...
(Date:7/31/2014)... July 31, 2014  A substantial share of ... about which therapies are included in formularies—say patient ... to a new Manhattan Research study, Taking ... study finds that P&T committee members in hospitals, ... (PBMs) have set a high bar for these ...
Breaking Medicine Technology:Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3
... , RYE, N.Y., Aug. 24 Curemark Founder ... at the Third International Epigenomics, Sequencing 2009 Conference at Harvard ... Dr. Fallon,s selection to address this cutting-edge conclave is particularly ... gene function that occur without a change in the DNA ...
... , , TITUSVILLE, N.J., Aug. 21 ... a complete response letter regarding the New Drug Application ... Ortho-McNeil-Janssen Pharmaceuticals, Inc. , , The ... Pharmaceutical Research and Development, L.L.C. (J&JPRD) on behalf of ...
Cached Medicine Technology:Curemark CEO Presents at Epigenomics Conference 2FDA Issues Complete Response Letter for Carisbamate 2FDA Issues Complete Response Letter for Carisbamate 3
(Date:8/1/2014)... 2014 Parker Waichman LLP, a national ... injured by defective medical devices and drugs reports that ... Ethicon surgical power morcellator devices used for the removal ... the spread of cancer associated with power morcellators, according ... 2014. , Johnson & Johnson had previously ceased ...
(Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- Almost 140 ... school transportation in the United States. But ... bus-related catastrophes, Dawne Gardner, injury prevention coordinator at ... Center, said in a medical center news release. ... returning to school, it,s important for parents and ...
(Date:8/1/2014)... Vegas, NV (PRWEB) August 01, 2014 ... and opportunities for independent community pharmacies. At ThoughtSpot ... pharmacists are equipped with practices and resources to ... Session, AmerisourceBergen leaders focused on critical issues to ... learn, optimize and grow. , ThoughtSpot show ...
(Date:8/1/2014)... 2014 The American Telemedicine Association ... (R-MS), and Peter Welch (D-VT), for their latest ... Parity Act of 2014, which improves telemedicine coverage ... to improve healthcare access and affordability using telecommunications ... ATA. "These cost-saving provisions are critical to improve ...
(Date:8/1/2014)... On Monday, June 30th, the Quirk Healthcare ... San Francisco, CA. Now in its fourth year, the ... Square hotel. , “We are excited about returning to ... ACA compliance issues,” Quirk Healthcare Foundation Executive Director, Ben ... guidance with NextGen implementation and use, electronic records documentation ...
Breaking Medicine News(10 mins):Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 3Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 4Health News:Expert Offers School Bus Safety Tips 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2
... Lucknow bench of Allahabad High Court today stayed operation ... per cent seats in unaided private medical// and dental ... quota., ,A division bench comprising Justice Pradeep Kant ... the GO on two petitions filed by Association of ...
... bird-borne Asian virus that has left a deadly trail ... has been adopted by the the Bill & Melinda ... expanding its geographic reach and threatens several billion people ... Japanese encephalitis program at Seattle-based Program for Appropriate Technology ...
... has been opened in the Marie Curie Cancer Care hospice in ... ,The unit has made provisions for 18 individual en-suite ... ,In addition the rooms can provide for a family member ... services at the hospice, Sue Curry, claimed that there were still ...
... with at least one year’s work experience would make ... educationalist philosopher in the Journal of Medical Ethics. ... Health Policy and Practice at the University of East ... the most suitable candidates for a career in medicine. ...
... may be on the decline.This follows a finding by the ... // that HIV infection rates have remained at a similar ... and in 2005 (30.2 per cent). ,Health Minister ... there was still a great deal of work needed to ...
... are suffering due to cuts in NHS expenditure, as councils ... ,The study, which has been commissioned by the ... 10 local authorities, in areas with a NHS deficit, have ... stepping back from jointly- funded projects and referring patients to ...
Cached Medicine News:Health News:Gates Foundation Adopts Fight against Encephalitis 2Health News:Gates Foundation Adopts Fight against Encephalitis 3Health News:Older, More Rounded, and Artier Applicants make Better Medical Students 2
... The F 250 is a portable system ... and temperature measurements. Temperature compensated pH results ... temperature probe (ATC) or a 3-in-1 electrode. ... three-point calibration with Auto-Find automatic buffer recognition ...
... highly accurate portable, waterproof system for pH, mV ... pH results can be obtained when used with ... • This GLP/GMP compliant system includes an RS-232 ... computer. Up to 100 data sets can be ...
... shelves. Over-sized compressor. Triple pane thermal ... Self-Contained System No plumbing required. Equipped ... Year Warranty on Parts & Labor and an ... Also available as a chromatography unit which includes ...
... controls for Digital Thermostat and Digital Display. ... , Interiorwhite anodized aluminum with 300 ... refrigeration (134A). , Temperature range 0C ... doors. , Foamed-in-place polyurethane high density ...
Medicine Products: